Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 45

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Pharmacotherapy in pediatric obesity: current evidence and landscape

Singhal, Vibha, Sella, Aluma Chovel, Malhotra, Sonali·2021·Current Opinion in Endocrinology, Diabetes & Obesity
DOI 10.1097/med.0000000000000587
Open this paper in CoChat — free account

Abstract

Purpose of review: Childhood obesity is escalating globally. Lifestyle and behavioral changes, which are the frequently used interventions in clinical practice, lead to only modest improvements in children with established obesity. Bariatric surgery is currently the most effective obesity treatment but has very limited utilization in pediatric obesity and is preferentially used for children with worsening comorbidities. There exists a massive treatment gap for children suffering with obesity especially after the failure of lifestyle modifications. Pharmacotherapy that is an established management tool in adults is very infrequently used in children. Only two medications, Phentermine and Orlistat are approved by the Food and Drug Administration (FDA) for use in adolescent obesity. Herein, we discuss the current landscape and available literature on the use of antiobesity pharmacotherapy in children. Recent findings: There are emerging pediatric data about the efficacy of the many weight loss medications that are FDA approved in adults. Moreover, more clinical trials are underway on the rarer, intractable forms of obesity such as monogenic, syndromic, and hypothalamic obesity. Summary: Weight loss medications in children, like adults, have variable efficacy and similar side effect profiles. Rigorous research and improved education of providers about weight loss medications may address the huge treatment gap in severe pediatric obesity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/med.0000000000000587

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 63

  1. Anderson, 2019, Understanding recent trends in childhood obesity in the United States, Econ Hum Biol, 34, 16, 10.1016/j.ehb.2019.02.002 · DOI
  2. Hales, 2017, Prevalence of obesity among adults and youth: United States, 2015–2016, NCHS Data Brief, 00, 1
  3. de la Haye, 2017, The dual role of friendship and antipathy relations in the marginalization of overweight children in their peer networks: the TRAILS study, PLoS One, 12, e0178130, 10.1371/journal.pone.0178130 · DOI
  4. Dietz, 1998, Childhood weight affects adult morbidity and mortality, J Nutr, 128, 411S, 10.1093/jn/128.2.411S · DOI · Paper page
  5. Ryder, 2019, Longitudinal changes in weight status from childhood and adolescence to adulthood, J Pediatr, 214, 187, 10.1016/j.jpeds.2019.07.035 · DOI
  6. Mead, 2017, Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years, Cochrane Database Syst Rev, 6, CD012651
  7. Al-Khudairy, 2017, Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years, Cochrane Database Syst Rev, 2017
  8. Lee, 2018, Epidemic obesity in children and adolescents: risk factors and prevention, Front Med, 12, 658, 10.1007/s11684-018-0640-1 · DOI · Paper page
  9. Goldschmidt, 2011, Importance of early weight change in a pediatric weight management trial, Pediatrics, 128, e33, 10.1542/peds.2010-2814 · DOI
  10. Armstrong, 2019, Section on obesity, section on surgery. pediatric metabolic and bariatric surgery: evidence, barriers, and best practices, Pediatrics, 144, e20193223, 10.1542/peds.2019-3223 · DOI · Paper page
  11. Ryder, 2017, Effect of phentermine on weight reduction in a pediatric weight management clinic, Int J Obes (Lond), 41, 90, 10.1038/ijo.2016.185 · DOI
  12. Fox, 2015, Topiramate for weight reduction in adolescents with severe obesity, Clin Pediatr (Phila), 54, 19, 10.1177/0009922814542481 · DOI
  13. O’Connor, 2017, Screening for obesity and intervention for weight management in children and adolescents: Evidence report and systematic review for the US Preventive Services Task Force, JAMA, 317, 2427, 10.1001/jama.2017.0332 · DOI · Paper page
  14. Weghuber, 2020, A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity, Pediatr Obes, 15, e12624, 10.1111/ijpo.12624 · DOI
  15. Maahs, 2006, Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents, Endocr Pract, 12, 18, 10.4158/EP.12.1.18 · DOI
  16. Chanoine, 2005, Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial, JAMA, 293, 2873, 10.1001/jama.293.23.2873 · DOI · Paper page
  17. Torgerson, 2004, XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients, Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 · DOI · Paper page
  18. Srivastava, 2018, Current pharmacotherapy for obesity, Nat Rev Endocrinol, 14, 12, 10.1038/nrendo.2017.122 · DOI · Paper page
  19. Woodard, 2020, Medications for the treatment of obesity in adolescents, Ther Adv Endocrinol Metab, 11, 2042018820918789, 10.1177/2042018820918789 · DOI
  20. Srivastava, 2019, Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity, Obesity (Silver Spring), 27, 190, 10.1002/oby.22385 · DOI
  21. Allison, 2012, Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP), Obesity (Silver Spring), 20, 330, 10.1038/oby.2011.330 · DOI · Paper page
  22. Gadde, 2011, Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 1341, 10.1016/S0140-6736(11)60205-5 · DOI · Paper page
  23. Narayanaswami, 2017, Obesity: current and potential pharmacotherapeutics and targets, Pharmacol Ther, 170, 116, 10.1016/j.pharmthera.2016.10.015 · DOI
  24. Greig, 2015, Naltrexone ER/Bupropion ER: A Review in Obesity Management, Drugs, 75, 1269, 10.1007/s40265-015-0427-5 · DOI
  25. Kweon, 2019, Effectiveness and safety of bupropion in children and adolescents with depressive disorders: a retrospective chart review, Clin Psychopharmacol Neurosci, 17, 537, 10.9758/cpn.2019.17.4.537 · DOI
  26. Khera, 2016, Association of pharmacological treatments for obesity with weight loss and adverse events, JAMA, 315, 2424, 10.1001/jama.2016.7602 · DOI · Paper page
  27. Greenway, 2010, Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 376, 595, 10.1016/S0140-6736(10)60888-4 · DOI · Paper page
  28. Inzucchi, 2014, Metformin in patients with type 2 diabetes and kidney disease, JAMA, 312, 2668, 10.1001/jama.2014.15298 · DOI · Paper page
  29. Frampton, 2018, Lisdexamfetamine dimesylate: a review in paediatric ADHD, Drugs, 78, 1025, 10.1007/s40265-018-0936-0 · DOI · Paper page
  30. Banaschewski, 2018, Growth and puberty in a 2-year open-label study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder, CNS Drugs, 32, 455, 10.1007/s40263-018-0514-8 · DOI
  31. Ichikawa, 2020, Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder, Neuropsychopharmacol Rep, 40, 52, 10.1002/npr2.12091 · DOI
  32. Gould, 2009, Sudden death and use of stimulant medications in youths, Am J Psychiatry, 166, 992, 10.1176/appi.ajp.2009.09040472 · DOI · Paper page
  33. Anders, 2006, ADHD drugs and cardiovascular risk, N Engl J Med, 354, 2296, 10.1056/NEJMc061187 · DOI
  34. Farr, 2016, Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study, Metab Clin Exp, 65, 945, 10.1016/j.metabol.2016.03.009 · DOI
  35. Schlögl, 2013, Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity, Diabetes Care, 36, 1933, 10.2337/dc12-1925 · DOI
  36. Kelly, 2013, The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial, JAMA Pediatr, 167, 355, 10.1001/jamapediatrics.2013.1045 · DOI
  37. Danne, 2017, Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years, J Pediatr, 181, 146, 10.1016/j.jpeds.2016.10.076 · DOI
  38. Patel, 2018, Safety and tolerability of new-generation antiobesity medications: a narrative review, Postgrad Med, 130, 173, 10.1080/00325481.2018.1435129 · DOI
  39. Linnebjerg, 2006, Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes, Diabet Med, 23, 240, 10.1111/j.1464-5491.2006.01800.x · DOI
  40. Gentilella, 2019, Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?, Diabetes Metab Res Rev, 35, e3070, 10.1002/dmrr.3070 · DOI
  41. Marbury, 2017, Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment, Clin Pharmacokinet, 56, 1381, 10.1007/s40262-017-0528-2 · DOI
  42. Chung, 2012, An overview of mongenic and syndromic obesities in humans, Pediatr Blood Cancer, 58, 122, 10.1002/pbc.23372 · DOI
  43. Geets, 2019, Clinical, molecular genetics and therapeutic aspects of syndromic obesity, Clinical Genetics, 95, 23, 10.1111/cge.13367 · DOI
  44. Sze, 2011, Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome, J Clin Endocrinol Metab, 96, E1314, 10.1210/jc.2011-0038 · DOI
  45. Senda, 2012, The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome, Endocr J, 59, 889, 10.1507/endocrj.EJ12-0074 · DOI
  46. Kim, 2020, Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome, Ann Pediatr Endocrinol Metab, 25, 52, 10.6065/apem.2020.25.1.52 · DOI
  47. Salehi, 2017, Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome, Pediatr Obes, 12, 221, 10.1111/ijpo.12131 · DOI
  48. Lawson, 2017, The effects of oxytocin on eating behaviour and metabolism in humans, Nat Rev Endocrinol, 13, 700, 10.1038/nrendo.2017.115 · DOI
  49. Thienel, 2016, Oxytocin's inhibitory effect on food intake is stronger in obese than normal-weight men, Int J Obes (Lond), 40, 1707, 10.1038/ijo.2016.149 · DOI
  50. Miller, 2017, Oxytocin treatment in children with Prader–Willi syndrome: a double-blind, placebo-controlled, crossover study, Am J Med Genet A, 173, 1243, 10.1002/ajmg.a.38160 · DOI
  51. Kuppens, 2016, Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial, Clin Endocrinol (Oxf), 85, 979, 10.1111/cen.13169 · DOI
  52. Farooqi, 2002, Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency, J Clin Invest, 110, 1093, 10.1172/JCI0215693 · DOI · Paper page
  53. Licinio, 2004, Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults, Proc Natl Acad Sci USA, 101, 4531, 10.1073/pnas.0308767101 · DOI · Paper page
  54. Clément, 2018, MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency, Nat Med, 24, 551, 10.1038/s41591-018-0015-9 · DOI · Paper page
  55. van Iersel, 2019, Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review, Endocr Rev, 40, 193, 10.1210/er.2018-00017 · DOI · Paper page
  56. Lomenick, 2016, A 52-week pilot study of the effects of exenatide on body weight and energy balance in patients with hypothalamic obesity, Obesity (Silver Spring), 24, 1222, 10.1002/oby.21493 · DOI
  57. Ando, 2014, Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity, Intern Med, 53, 1791, 10.2169/internalmedicine.53.1646 · DOI
  58. Ashraf, 2018, Liraglutide for the treatment of hypothalamic obesity, AACE Clinical Case Reports, 4, e342, 10.4158/ACCR-2018-0009 · DOI
  59. Zoicas, 2013, GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases, Eur J Endocrinol, 168, 699, 10.1530/EJE-12-0997 · DOI
  60. Denzer, 2019, Treatment of hypothalamic obesity with dextroamphetamine: a case series, Obes Facts, 12, 91, 10.1159/000495851 · DOI · Paper page
  61. Hamilton, 2011, Hypothalamic obesity following craniopharyngioma surgery: results of a pilot trial of combined diazoxide and metformin therapy, Int J Pediatr Endocrinol, 2011, 417949, 10.1155/2011/417949 · DOI · Paper page
  62. Fox, 2016, Meal-replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial, Obesity (Silver Spring), 24, 2553, 10.1002/oby.21633 · DOI
  63. Kelly, 2012, Exenatide as a weight-loss therapy in extreme pediatric obesity a randomized, controlled pilot study, Obesity (Silver Spring), 20, 364, 10.1038/oby.2011.337 · DOI

Cited by

Metadata

Authors
Singhal, V., Sella, A. C., & Malhotra, S.
Affiliations
Division of Pediatric Endocrinology, Massachusetts General Hospital, Harvard Medical School
Venue
Current Opinion in Endocrinology, Diabetes & Obesity
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2020-11-12
Volume
28
Issue
1
Pages
55-63
ISSN
  • 1752-296X
  • 1752-2978
DOI
10.1097/med.0000000000000587
Cited by
45
References
17
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.